NCT06702995 - Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

April 19, 2023

Primary Completion Date

May 13, 2026

Study Completion Date

July 19, 2026

Conditions

Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG

XNW5004

Oral continuous

DRUG

enzalutamide

enzalutamide 160 mg (four 40 mg capsules) orally once daily

Trial Locations (2)

RECRUITING

270 Dongan Road, Shanghai, Shanghai

RECRUITING

Cancer Hosipital of Shandong First Medical University,440 Jiyan Road, Jinan City, Shandong Province, Jinan